New drug combo shows promise in saving voice boxes of cancer patients

This study tested a treatment that combines two chemotherapy drugs (cisplatin and docetaxel) with an immunotherapy drug (pembrolizumab) in 28 patients with stage II or III laryngeal cancer. The goal was to see if this approach could control the cancer and allow patients to keep their larynx (voice box). After four cycles, 75% of patients had no cancer detectable in tissue samples. The treatment aims to control the disease, not cure it, and patients may need ongoing monitoring or additional therapy.